Search for: [Abstract = "Gastroesophageal reflux disease is a set of ailments caused by the pathological regurgitation of food content from the stomach into the oesophagus. GERD occurs in 20 \- 40% of developing countries, in Poland in about 34% of the population, which is a serious epidemiological problem. Gastroesophageal reflux disease is not only connected to a high physical burden, but also reduces the quality of life of patients, thus contributing to poorer functioning in the sphere of professional, social and family life. Effective GERD therapy is based on pharmacotherapy and modification of the patient's diet and lifestyle. Proton pump inhibitors \(PPIs\) remain the basis of pharmacotherapy of gastroesophageal reflux disease. Due to the high morbidity and recurrence of the disease, and on the other hand, easy access to PPIs as part of OTC sales, which allows patients to continue their own therapy, often without monitoring, there is an increasing risk of incorrect use and even abuse of these drugs, which can have dangerous consequences for health. The aim of the study was to assess the impact of pharmaceutical care on the efficacy and safety of gastroesophageal reflux disease therapy in patients taking proton pump inhibitors or antagonists of H2 receptor. The project was an open intervention study conducted in a community pharmacy, the intervention was the pharmaceutical care service. The interve"]

Number of results: 1